ArticlePloS one2018
Duration of travel-associated faecal colonisation with ESBL-producing Enterobacteriaceae - A one year follow-up study.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Acquisition of multidrug-resistant Enterobacterales during international travel: a systematic review of clinical and microbiological characteristics and meta-analyses of risk factors.Antimicrobial resistance and infection control · 2020Pooled it
- Duration and predictors of colonization with MDRInfection prevention in practice · 2026Article
- Intestinal colonisation with extended-spectrum beta-lactamase-producing Enterobacterales and the impact of selected factors on intestinal colonisation duration: a prospective cohort study.Antimicrobial resistance and infection control · 2025Article
- The overlooked bacterial pandemic.Seminars in immunopathology · 2024Review
- Gut microbiome perturbation, antibiotic resistance, and Escherichia coli strain dynamics associated with international travel: a metagenomic analysis.The Lancet. Microbe · 2023Article
- A parallel and silent emerging pandemic: Antimicrobial resistance (AMR) amid COVID-19 pandemic.Journal of infection and public health · 2023Review
- Travel-related gastrointestinal diseases: Assessment and management.Public health challenges · 2022Review
- Mortality in Thai Nursing Homes Based on Antimicrobial-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Carriage of Multidrug-Resistant Bacteria in Healthy People: Recognition of Several Risk Groups.Antibiotics (Basel, Switzerland) · 2021Review
- Import of multidrug-resistant bacteria from abroad through interhospital transfers, Finland, 2010-2019.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021Observational
- Travel-associated multidrug-resistant organism acquisition and risk factors among US military personnel.Journal of travel medicine · 2021Observational
- Article
- Risk Factors and Prevalence ofFrontiers in microbiology · 2021Article
- Evolutionary causes and consequences of bacterial antibiotic persistence.Nature reviews. Microbiology · 2020Review
- The Novel Coronavirus COVID-19 Outbreak: Global Implications for Antimicrobial Resistance.Frontiers in microbiology · 2020Article
- The pandemic Escherichia coli sequence type 131 strain is acquired even in the absence of antibiotic exposure.PLoS pathogens · 2019Review
- Investigating Understandings of Antibiotics and Antimicrobial Resistance in Diverse Ethnic Communities in Australia: Findings from a Qualitative Study.Antibiotics (Basel, Switzerland) · 2019Article
- Risk factors associated with prolonged intestinal colonization of ESBL-producingInfection and drug resistance · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn a previous study, we found that 30% of individuals travelling outside Scandinavia acquired extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) in their faecal flora. The aim of this study was to determine the duration of travel-associated faecal colonisation with ESBL-PE, to assess risk factors for prolonged colonisation and to detect changes in antibiotic susceptibility during prolonged colonisation.
methodsIndividuals with travel-associated colonisation with ESBL-PE submitted faecal samples every 3rd month over a one-year period. A questionnaire was completed at the beginning and end of follow-up. All specimens were analysed for ESBL-PE, and all isolates underwent confirmatory phenotype testing as well as molecular characterisation of ESBL-genes. Minimum inhibitory concentrations (MIC) for beta-lactam and non-beta-lactam agents were determined using the Etest.
resultsAmong 64 participants with travel-associated colonisation with ESBL-PE, sustained carriage was seen in 20/63 (32%), 16/63 (25%), 9/63 (14%) and 7/64 (11%) at 3, 6, 9 and 12 months after return from their journey, respectively. The majority, 44 (69%) of travellers were short-term carriers with ESBL-PE only detected in the initial post-travel stool sample. Evaluation of risk factors demonstrated a decreased risk of becoming a long-term carrier among travellers with diarrhoea while abroad and a history of a new journey during the follow-up period. High susceptible rates were demonstrated to carbapenems (97-100%), temocillin (95%), mecillinam (97%), amikacin (98%), fosfomycin (98%), nitrofurantoin (99%) and tigecycline (97%).
conclusionTravel-associated faecal colonisation with ESBL-PE appears to be transient and generally brief. Diarrhoea while abroad or a new trip abroad during the follow-up period decreased the risk of becoming a long-term carrier. Only 11% of travellers who acquired ESBL-PE during their travels had sustained colonisation 12 months after return.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.